Evaluation of [ 89 Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.

MLA

Dehdashti, Farrokh, et al. “Evaluation of [ 89 Zr]Trastuzumab-PET/CT in Differentiating HER2-Positive from HER2-Negative Breast Cancer.” Breast Cancer Research and Treatment, vol. 169, no. 3, June 2018, pp. 523–30. EBSCOhost, https://doi.org/10.1007/s10549-018-4696-z.

APA

Dehdashti, F., Wu, N., Bose, R., Naughton, M. J., Ma, C. X., Marquez-Nostra, B. V., Diebolder, P., Mpoy, C., Rogers, B. E., Lapi, S. E., Laforest, R., & Siegel, B. A. (2018). Evaluation of [ 89 Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. Breast Cancer Research and Treatment, 169(3), 523–530. https://doi.org/10.1007/s10549-018-4696-z

Chicago

Dehdashti, Farrokh, Ningying Wu, Ron Bose, Michael J Naughton, Cynthia X Ma, Bernadette V Marquez-Nostra, Philipp Diebolder, et al. 2018. “Evaluation of [ 89 Zr]Trastuzumab-PET/CT in Differentiating HER2-Positive from HER2-Negative Breast Cancer.” Breast Cancer Research and Treatment 169 (3): 523–30. doi:10.1007/s10549-018-4696-z.